Locally advanced nonesmall-cell lung cancer (NSCLC) is curable. Standard treatment is concurrent chemoradiotherapy, but its efficacy with cytotoxic agents seems to reach a plateau. Among patients with advanced NSCLC who have epidermal growth factor receptor (EGFR) mutation, EGFR-tyrosine kinase inhibitor is the key drug. Thus, a similar strategy should be tested in patients with locally advanced NSCLC who have EGFR mutation. This single arm, phase II study aims to explore the efficacy and tolerability of gefitinib with concurrent thoracic radiotherapy in patients with unresectable stage III NSCLC harboring EGFR mutations. The primary endpoint is progression-free survival rate at 2 years. The secondary endpoints are overall response rate, progression-free survival, overall survival, and safety. A total of 27 patients will be enrolled in this trial.
Introduction
Locally advanced nonesmall-cell lung cancer (LA-NSCLC) is a curable disease, and the standard treatment is concurrent chemoradiotherapy (CRT). Although newer cytotoxic agents have been tested, their efficacy results seem to reach a plateau. 1 Another strategy to improve treatment outcome is to introduce novel agents, like molecular targeted drugs or immune-checkpoint inhibitors. Recently, the programmed death ligand-1 inhibitor, durvalumab, significantly prolonged progression-free survival (PFS) among patients with LA-NSCLC who responded to CRT in a phase III PACIFIC trial. 2 However, its subset analysis showed that epidermal growth factor receptor (EGFR)-mutated patients did not benefit from durvalumab. Retrospective studies suggest that about 30% of patients with LA-NSCLC have EGFR mutation. 3, 4 Another regimen should thus be developed for this population. 1 Among patients with NSCLC who have sensitive EGFR mutation, EGFR-tyrosine kinase inhibitor (TKI) is the key drug. 5, 6 Overall response rate (ORR) with EGFR-TKI is about double that of platinum-doublet chemotherapy. In addition, a preclinical study suggested that gefitinib had a radio-sensitizing effect. 7 These rationales suggest that EGFR-TKI plus thoracic radiotherapy should be tested for EGFR-mutated LA-NSCLC. Several studies using gefitinib monotherapy combined with thoracic radiotherapy have been conducted, but all of them allowed participation of both EGFR-mutated and wild-type patients. In one study, 2 of 3 patients who lived more than 5 years after gefitinib plus thoracic radiotherapy were later proved to harbor the EGFR mutation. 8 Another study showed the feasibility of gefitinib plus concurrent thoracic radiotherapy where the incidence of interstitial lung disease was about 2.9%. 9 This was comparable to that with gefitinib monotherapy in Japanese patients with EGFR-mutated NSCLC. 10 Based on this information, we planned a phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III NSCLC harboring EGFR mutations (WJOG6911L). Here, we introduce the details of this study.
Protocol of Study WJOG6911L

Objectives
This study aims to explore the efficacy and the tolerability of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III NSCLC harboring EGFR mutations.
Study Design
This is a single-arm, prospective phase II study. An overview is shown in Figure 1 .
Endpoints
The primary endpoint is set as the PFS rate at 2 years according to the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. Secondary endpoints are ORR, PFS, overall survival, and safety. 
Treatment
Treatment consists of gefitinib monotherapy plus concurrent thoracic radiotherapy. An oral dose of 250 mg of gefitinib is administered daily beginning on day 1, for 2 years. Thoracic radiotherapy is also be started on day 1 and delivered 5 days per week in 2-Gy fractions to a total dose of 64 Gy. Before registration, positron emission tomography-computed tomography (PET-CT) must be taken, and 3-dimensional CT planning is mandatory. Involved-field radiotherapy is adopted in this study to avoid the risk of gefitinib-induced interstitial pneumonia. Gross tumor volume consists of the primary tumor and clinically positive lymph nodes seen either on the planning CT (>1 cm short axis diameter) or pretreatment PET scan. The clinical target volume includes gross tumor volume plus a total margin of at least 0.5 cm. The total planning target volume includes the clinical target volume plus a total margin of at least 0.5 cm. The dose was prescribed at a reference point. The planning target volume is encouraged to cover 95% to 107% of prescribed dose. All doses of radiation are calculated with inhomogeneity corrections (superposition/convolution dose calculation algorithms). The maximum spinal cord dose is limited to 52 Gy, and 1 cc of spinal cord should not exceed 48 Gy. The volume of both lungs that receive 20 Gy (V20) should not exceed 35% of the total. Brachial plexus doses should be kept below 66 Gy.
RT Quality Assurance Review
For the radiotherapy quality assurance review, we collected the Digital Imaging and Communications in Medicine data of the pretreatment diagnostic chest radiographs; CT and PET-CT; CT planning and portal images; radiotherapy planning data including dose distribution, structures, and plan summaries; and radiotherapy charts of all patients.
Follow-up and Assessment
To assess the efficacy, chest CT is taken every 2 months for the first 6 months, and every 6 months after that. Brain magnetic Gefitinib Plus Thoracic Radiation in Stage III NSCLC (WJOG6911L) resonance imaging is taken once a year. Adverse events are graded using the Common Terminology Criteria for Adverse Events, version 4.0.
Statistical Analysis
We previously reported that the PFS rate at 2 years could be a reliable surrogate maker for the 5-year survival rate in patients with LA-NSCLC. 11 Thus, the PFS rate at 2 years is set as the primary endpoint of this study. Based on the Kaplan-Meier curve of PFS in the pivotal study of CRT, 12 we assumed an improved PFS rate at 2 years from 20% to 40%. Twenty-five eligible patients were required to ensure a statistical power of 0.75 at a 1-sided score test with an alpha error of 0.05. Assuming that around 5% ineligibles will be identified after the recruitment, 27 patients are recruited.
Ethical Considerations
The study is conducted in compliance with the principles of the Declaration of Helsinki. The protocol was approved by the institutional review board of each participating institution. Written informed consent is obtained from all patients before any screening or inclusion procedures. This protocol was registered at the website of University Hospital Medical Information Network, Japan (protocol identification no. UMIN000008366).
Discussion and Conclusion
Among patients with metastatic NSCLC with oncogenic driver mutations, molecular targeted drugs have dramatically changed the standard treatment. Therefore, introduction of these agents into treatment for LA-NSCLC seems to be a reasonable approach. Several studies to test the utility of EGFR-TKI concurrent with radiotherapy did not show significant results, mainly owing to patient selection. This study is the first to explore the efficacy and tolerability of gefitinib monotherapy concurrent with radiotherapy in EGFR-mutated, unresectable LA-NSCLC. We believe that the results of this study will impact on the future strategy toward this population.
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